Seattle Genetics Inc.

(SGEN) Trade

By |

Profile

Seattle Genetics is a biotech firm focused on the development of monoclonal antibody-based therapies. The company's lead product, Adcetris, has received approval for advanced frontline, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. The company has several other early-stage programs in trials. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Contact Information

Website: www.seattlegenetics.com
Email: investors@seagen.com
Main Phone: +1 425 527-4000
Address: 21823 - 30th Drive South East
Address 2: Building 3
State: WA
City / Town: Bothell
Country: USA
Postal Code: 98021

Issuer Information

Exchange: NGS
CEO: Clay B. Siegall
Employees: 1100
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)
$ 61.18 $ -0.77 (-1.24%)
Last Price 61.18 Change $ -0.77 Change % -1.24 Tick N/A
Bid 61.10 Bid Size 100.00 Ask 61.26 Ask Size 100.00
Open 61.86 High 62.88 Low 60.80 Prev Close 61.95
Last Trade Volume 90,776 52 Wk Hi 84.37 52 Wk Low 47.75
Market Cap 9.8 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 160,145,888.00 EPS (TTM) -1.10 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 52 170
Number of Buys 41 106
Number of Sells 11 64
Net Activity 1537290 5601762
Last 10 Buys Shares
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Last 10 Sell Shares
Clay B. Siegall 1,000
Clay B. Siegall 1,000
Vaughn B. Himes 1,000
Vaughn B. Himes 1,000
Vaughn B. Himes 1,000
Darren S. Cline 1,000
Clay B. Siegall 1,000
Clay B. Siegall 1,000
Clay B. Siegall 1,000
Darren S. Cline 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 77 77 77 80
Low Target Price Estimate 50 50 50 50
Mean Target Price Estimate 64.82 64.64 64.64 66.64
Standard Deviation 9.23 9.31 9.31 10.11
Date of Most Recent Estimate 06/04/18 05/17/18 05/17/18 06/11/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 6 5 5 6
Moderate Buy 2 2 3 3
Hold 5 6 6 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.92 2.08 2.04 1.97